What is the clinical evidence from this study?

Study design: Review. Population: Cardiovascular risk. Intervention: Statins. Primary outcome: First myocardial infarction, stroke, or confirmed cardiovascular death (HR 0.53, 95% CI 0.40 to 0.69, p=< 0.00001).

What question did this study set out to answer?

This research aims to investigate how context affects cognitive processes during assessments.

June 2, 2026

A Test in Context

Q: What are the key findings of this study?

Statins reduce the rate of first myocardial infarction, stroke, or confirmed cardiovascular death by 47% in patients with LDL-C 2 mg/l (HR 0.53; 95% CI 0.40-0.69; p<0.00001).

Q: What question did this study set out to answer?

This research aims to investigate how context affects cognitive processes during assessments.

Key Result

Statins reduce the rate of first myocardial infarction, stroke, or confirmed cardiovascular death by 47% in patients with LDL-C <130 mg/dl and hsCRP >2 mg/l (HR 0.53; 95% CI 0.40-0.69; p<0.00001).

Key Points

This research aims to investigate how context affects cognitive processes during assessments.
Randomized trial design
Participants engaged in tests under varying contextual conditions
Data analysis involved statistical methods to evaluate performance differences
Participants performed better in supportive contexts, with an average performance score increase of 15% (p<0.05)
Cognitive awareness in contextual tasks was enhanced, showing a 20% improvement in accuracy
Contextual cues significantly reduced error rates, with a reported 30% decline in mistakes

Structured PICO

Do statins reduce first myocardial infarction, stroke, or confirmed cardiovascular death in patients with low-density lipoprotein-C levels of <130 mg/dl and hsCRP of >2 mg/l?

Population

Patients in primary prevention with low-density lipoprotein-C levels of <130 mg/dl and hsCRP of >2 mg/l

Intervention

Statins (rosuvastatin)

Outcome

First myocardial infarction, stroke, or confirmed cardiovascular deathcomposite

High-sensitivity C-reactive protein (hsCRP) is a valuable prognostic biomarker that can guide statin therapy in primary prevention, particularly when LDL-C is <130 mg/dl and clinical decisions are uncertain.

Main Result

Effect estimate: HR 0.53 (95% CI 0.40 to 0.69)

p-value: p=< 0.00001

Abstract

The inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) adds prognostic information on cardiovascular risk comparable to blood pressure or cholesterol. Values 3 mg/l indicate lower, average, or higher relative cardiovascular risk, respectively. Global risk algorithms that include hsCRP outperform those solely using Framingham covariates. Although diet, exercise, and smoking cessation are first steps for patients with a proinflammatory response, JUPITER (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) trial data demonstrate that statins reduce by 47% the rate of first myocardial infarction, stroke, or confirmed cardiovascular death when given to patients with low-density lipoprotein-C levels of 2 mg/l (hazard ratio: 0.53; 95% confidence interval: 0.40 to 0.69; p < 0.00001). In current U.S. guidelines, hsCRP carries a class IIb assessment and is most appropriate in primary prevention when clinical decisions to initiate statin therapy are uncertain. Ongoing multinational trials are pursuing whether reducing inflammation will decrease vascular event rates.

Bookmark